Advertisement

The Bone Metastases Quality of Life Questionnaire

  • X. Badia
  • A. Vieta
  • M. Gilabert

Abstract:

The  Bone Metastases Quality of Life Questionnaire (BOMET-QOL) is the first  bone metastases-specific HRQOL measure. It is a simple, self-administered questionnaire intended for use in clinical research and in the routine monitoring of patients with malignant bone disease due to neoplasia. The BOMET-QOL questionnaire is unidimensional and consists of 10 items that can be answered according to a Likert scale with five categories scoring from 0 to 4. The timeframe refers to “last week.” The items refer to HRQOL topics such as pain, mobility, vitality, sex life, worries about the future, perceptions and daily activities. The global score is calculated by adding up the answers obtained in each item, and may range from 0 (worst HRQOL) to 40 (best HRQOL). These scores are standardized to make it easier to interpret the scoring, with the final scores ranging from 0 (worst HRQOL) to 100 (best HRQOL). The BOMET-QOL was developed in three phases. The item generation phase was performed by means of a literature search, a panel of experts and 15 semi-structured interviews with patients. An initial set of 179 expressions was identified. The item selection phase consisted of the identification of the initial group of items. The 15 experts carried out a qualitative and quantitative reduction of the 179 expressions according to their clarity, frequency and importance. This phase resulted in the 35-item version of the BOMET-QOL. The item reduction phase was carried out in two steps. The initial reduction yielded a 25-item questionnaire. This was administrated to a non-randomized sample of 92 patients with malignant bone disease due to neoplasia (MBDN) and the reduction was carried out via factorial analysis. Similarly, the BOMET-QOL-25 was reduced to an integrated version of 10 items by means of a sample of 263 oncology patients. It was then validated, showing high homogeneity, good reproducibility and significant correlations with the ECOG and the EORTC-QLQ-C30 questionnaire. The BOMET-QOL questionnaire is a feasible (easy and user-friendly), reliable and specific 10-item instrument for assessing HRQOL in patients with MBDN.

Keywords

Bone Metastasis Baseline Visit Good HRQOL Common Clinical Practice Longitudinal Validity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:

BM

 bone metastases

BOMET-QOL

bone metastases quality of life questionnaire

CARES

cancer rehabilitation evaluation system

FACT-G

functional assessment of cancer therapy

HRQOL

health-related quality of life

MBDN

malignant bone disease due to neoplasia

PMI

 pain management index

QLQ- 30

quality of life questionnaire

RSCL

Rotterdam symptom check list

References

  1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, M. de Haes JCJ, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F. (1993). J Natl Cancer Inst. 85: 365–376.PubMedCrossRefGoogle Scholar
  2. Adrover E, Allepuz J, Sureda A, Domine M, Barnadas A, Constela M, Lluch A, Ruiz M, Piera J, Mayordomo JI, Morales A, Muñoz M, Alcover J, Colomer R, Llombart A, Massutti B, Carballido J, Garrido P, García R, Badia X, Lizan L, Gilabert M. (2005). J Outcomes Res. 9: 15–27.Google Scholar
  3. Avis NE, Smith KW, Hambleton RK, Feldman HA, Selwyn A, Jacobs A. (1996). Med Care. 34: 1102–1120.PubMedCrossRefGoogle Scholar
  4. Badia X, Muriel C, Gracia A, Núñez-Olarte JM, Perulero N, Gálvez R, Carulla J, Cleeland CS, Vesbpi G. (2003). Med Clin (Barc). 120: 52–59.CrossRefGoogle Scholar
  5. Bezjak A, Taylor KM, Macdonald K, DePetrillo AD. (1998). Cancer Pre Control. 2: 230–235.Google Scholar
  6. Bunting RW, Shea B. (2001). Cancer. 92(Suppl. 4): 1020–1028.PubMedCrossRefGoogle Scholar
  7. Cella D, Chang CH, Lai JS, Webster K. (2002). Semin Oncol. 29(Suppl. 8): 60–68.PubMedCrossRefGoogle Scholar
  8. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P and Brannon J. (1993). J Clin Oncol. 11: 570–579.PubMedGoogle Scholar
  9. Cleeland CS. (1991). Cancer. 67: 823–827.PubMedCrossRefGoogle Scholar
  10. Coleman R. (2004). Oncologist. 9: 14–27.PubMedCrossRefGoogle Scholar
  11. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A. (2002). Cochrane Database Syst Rev. 4: CD003188.Google Scholar
  12. Ganz PA, Schag CA, Lee JJ, Sim MS. (1992). Qual Life Res. 1: 19–29.PubMedCrossRefGoogle Scholar
  13. Lipton A. (2003). Curr Treat Options Oncol. 4: 151–158.PubMedCrossRefGoogle Scholar
  14. Martinez MJ, Roque M, Alonso-Coello P, Català E. (2003). Cochrane Database Syst Rev. 3: CD003223.PubMedGoogle Scholar
  15. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. (1982). Am J Clin Oncol. 5: 649–655.PubMedCrossRefGoogle Scholar
  16. Prieto L, Alonso J, Lamarca R. (2003). Health Qual Life Outcomes. 28: 1–27.Google Scholar
  17. Rasch G. (1993). Probabilistic Models for Some Intelligence and Attainment Tests. Paedagogiske Institut, Copenhagen.Google Scholar
  18. Reddi AH, Roodman D, Freeman C, Mohla S. (2003). J Bone Miner Res. 18: 190–194.PubMedCrossRefGoogle Scholar
  19. Sureda A, Isla D, Cózar JM, Ruiz M, Domine M, Margelí M, Edrover E, Ramos M, Pastor M, Martín A, Llombart A, Massuti B, Muñoz M, Barnadas A, Fernández J, Colomer R, Allepuz C, Gilabert M, Badia X. (2007). JME. 10: 27–39.Google Scholar
  20. Watson M, Law M, Maguire GP, Robertson B, Greer S, Bliss JM, Ibbotson T. (1992). Psychooncology. 1: 35–44.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2010

Authors and Affiliations

  • X. Badia
  • A. Vieta
  • M. Gilabert

There are no affiliations available

Personalised recommendations